Figure 1
![Figure 1. Association of CD33 expression with cytogenetic and molecular markers. (A) CD33 expression of 621 AML patient samples, subgrouped into 3 terciles. (B) Two representative examples of CD33 expression on primary AML blasts (tercile 1 [T1], left; tercile 3 [T3], right). (C-D) CD33 expression intensity correlated to specific cytogenetic/molecular markers. *Including abn(3q), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q), −5/5q-, −7, add(7q)/del(7q), t(v;11)(v;q23), t(9;22)(q34;q11), −17/abn(17p), but excluding t(3;5)(q21∼25;q31∼35), t(9;11)(p21-22;q23) and t(11;19)(q23;p13). †Including t(9;11)(p21-22;q23), t(11;19)(q23;p13) and all other abnormalities not otherwise classified.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/3/10.1182_blood-2013-08-523548/4/356f1.jpeg?Expires=1735808978&Signature=sEJBS4p4llGLklerpgFbHTMxNagTfARYtsu9YTwL6u2SQaGj7oJRm9NfPX~ugT5r~S1n3rP8PBkMJpkKL1UZ1TYW72EHgR-CU7qDpDdUsHl0zjVPBHACtbA5-Nv~E4RZcsRGf5GGgq6QKYzUnaAPKVd5tYFIbtwLmq5mmazQVj67jarVeY1vdApayGKmRugVqDJ3RUSnwWDgz7ZZ1CzvBYvuvjV90XnEK499~G45V2tT-jLEjUw1J7RB~RbjnG1ahnZbC49Ryx3QeBeoZpMRMg6EY2GoykkPtYIGqwzkt65DZtQMUJJESvNVDu5y~I4WqqNaxabgt5CZV8UnppsIsA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Association of CD33 expression with cytogenetic and molecular markers. (A) CD33 expression of 621 AML patient samples, subgrouped into 3 terciles. (B) Two representative examples of CD33 expression on primary AML blasts (tercile 1 [T1], left; tercile 3 [T3], right). (C-D) CD33 expression intensity correlated to specific cytogenetic/molecular markers. *Including abn(3q), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q), −5/5q-, −7, add(7q)/del(7q), t(v;11)(v;q23), t(9;22)(q34;q11), −17/abn(17p), but excluding t(3;5)(q21∼25;q31∼35), t(9;11)(p21-22;q23) and t(11;19)(q23;p13). †Including t(9;11)(p21-22;q23), t(11;19)(q23;p13) and all other abnormalities not otherwise classified.
